HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels.
Maria RendinaErnesto PaolettiNunzia LabarileAntonella MarraAndrea IannoneAntonino CastellanetaElisabetta BussalinoMaura RaveraAntonio SchenaNicola M CastellanetaMichele BaroneSimona SimoneLoreto GesualdoAlfredo Di LeoPublished in: Therapeutic advances in chronic disease (2022)
DAA therapy is safe and effective in HCV-positive KTRs. It also produces a persistent significant reduction in Tac trough levels that does not influence graft function at 12 months.